Surmodics Inc (SRDX) 29.48 $SRDX SurModics Shar
Post# of 273257
Posted On: 09/04/2016 7:24:38 AM
Surmodics Inc (SRDX) 29.48 $SRDX
SurModics Shares Up 40.8% Since SmarTrend's Buy Recommendation (SRDX)
Comtex SmarTrend(R) - Fri Sep 02, 12:49PM CDT
SmarTrend identified an Uptrend for SurModics (NASDAQ:SRDX) on January 28th, 2016 at $20.44. In approximately 7 months, SurModics has returned 40.84% as of today's recent price of $28.78.
SRDX: 29.48 (+1.24)
SurModics Has Returned 41.2% Since SmarTrend Recommendation (SRDX)
Comtex SmarTrend(R) - Fri Aug 26, 12:17AM CDT
SmarTrend identified an Uptrend for SurModics (NASDAQ:SRDX) on January 28th, 2016 at $20.44. In approximately 7 months, SurModics has returned 41.23% as of today's recent price of $28.86.
SRDX: 29.48 (+1.24)
Surmodics to Present at 5th Annual InvestMNt Conference on August 24
BusinessWire - Tue Aug 16, 7:05AM CDT
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that the Company will present at the 2016 InvestMNt conference sponsored by CFA Society Minnesota.
SRDX: 29.48 (+1.24)
39.0% Return Seen to Date on SmarTrend SurModics Call (SRDX)
Comtex SmarTrend(R) - Thu Aug 11, 12:16AM CDT
SmarTrend identified an Uptrend for SurModics (NASDAQ:SRDX) on January 28th, 2016 at $20.44. In approximately 7 months, SurModics has returned 39.03% as of today's recent price of $28.41.
SRDX: 29.48 (+1.24)
Shares of SRDX Up 36.6% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Aug 03, 12:42PM CDT
SmarTrend identified an Uptrend for SurModics (NASDAQ:SRDX) on January 28th, 2016 at $20.44. In approximately 6 months, SurModics has returned 36.63% as of today's recent price of $27.92.
SRDX: 29.48 (+1.24)
Surmodics IVD Launches Breakthrough StabilBlock(R) Immunoassay Stabilizer
BusinessWire - Mon Aug 01, 6:05AM CDT
Surmodics, Inc. (NASDAQ: SRDX), the global leader in chemical components for in vitro diagnostic (IVD) tests and microarrays, has announced the launch and immediate availability of StabilBlock(R), its most advanced Immunoassay Stabilizer. StabilBlock Immunoassay Stabilizer is the best available reagent for reducing non-specific binding to boost immunoassay signal-to-noise ratios.
SRDX: 29.48 (+1.24)
Surmodics Reports Third Quarter Fiscal 2016 Results
BusinessWire - Thu Jul 28, 6:30AM CDT
--GAAP EPS of $0.30, Non-GAAP EPS of $0.37
SRDX: 29.48 (+1.24)
Myriad Genetics Buys Sividon Diagnostics, Gains EndoPredict
Zacks Equity Research - Zacks Investment Research - Fri Jun 03, 7:59AM CDT
With the global cancer diagnostic market currently expected to grow at a CAGR of 7.6% to $168.6 billion by 2020; we expect the Sividon acquisition to open up more opportunities for Myriad (MYGN) in this market.
BSX: 24.26 (-0.07), SRDX: 29.48 (+1.24), MYGN: 20.65 (+0.21), BAX: 46.28 (+0.10)
SurModics to Present at Jefferies Healthcare Conference
BusinessWire - Wed Jun 01, 7:05AM CDT
SurModics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies, today announced that Gary Maharaj, president and chief executive officer, and Andy LaFrence, vice president of finance and chief financial officer, will make a presentation to the investment community at the Jefferies Healthcare Conference in New York City on Tuesday, June 7, 2016, at 4 p.m. ET (3 p.m. CT).
SRDX: 29.48 (+1.24)
GNC Holdings Q1 Results Weak, Overseas Prospects Bright
Zacks Equity Research - Zacks Investment Research - Wed Jun 01, 7:01AM CDT
GNC Holdings (GNC) made a disappointing start to its first quarter of 2016 with the results squarely missing the Zacks Consensus Estimate.
BSX: 24.26 (-0.07), SRDX: 29.48 (+1.24), BAX: 46.28 (+0.10), GNC: 20.74 (-0.07)
Thermo Fisher to Buy FEI, Boost Electron Microscopy Platform
Zacks Equity Research - Zacks Investment Research - Tue May 31, 7:58AM CDT
The FEI deal is expected to be accretive to Thermo Fisher's (TMO) adjusted EPS by 30 cents in the first full year after close.
BSX: 24.26 (-0.07), SRDX: 29.48 (+1.24), TMO: 151.18 (+0.23), BAX: 46.28 (+0.10), FEIC: 106.61 (+0.05)
IDEXX Laboratories: Strong Instrument Placement Drives Q1
Zacks Equity Research - Zacks Investment Research - Mon May 30, 7:12AM CDT
IDEXX (IDXX) started off 2016 on a strong note, with its first-quarter results squarely beating the Zacks Consensus Estimate.
BSX: 24.26 (-0.07), SRDX: 29.48 (+1.24), BAX: 46.28 (+0.10), IDXX: 114.09 (+0.93)
Cepheid: GeneXpert Placements High, Currency Woes Stay
Zacks Equity Research - Zacks Investment Research - Fri May 27, 6:51AM CDT
Cepheid (CPHD) started 2016 on a promising note with its first-quarter results squarely beating the Zacks Consensus Estimate.
BSX: 24.26 (-0.07), SRDX: 29.48 (+1.24), BAX: 46.28 (+0.10), CPHD: 34.42 (+0.16)
Qiagen, Therawis Diagnostics to Develop Breast Cancer Test
Zacks Equity Research - Zacks Investment Research - Fri May 27, 6:47AM CDT
With the global cancer diagnostic market expected to grow at a CAGR of 7.6% to $168.6 billion by 2020, we expect Qiagen (QGEN) to garner higher profits on account of this collaboration.
BSX: 24.26 (-0.07), SRDX: 29.48 (+1.24), BAX: 46.28 (+0.10), QGEN: 26.63 (+0.17)
ResMed Posts Mixed Q3 Results, Brightree Buyout on Track
Zacks Equity Research - Zacks Investment Research - Thu May 26, 7:35AM CDT
ResMed (RMD) posted a lackluster third-quarter fiscal 2016. Nevertheless, ResMed's segmental as well as geographical performance was strong.
BSX: 24.26 (-0.07), SRDX: 29.48 (+1.24), BAX: 46.28 (+0.10), RMD: 67.06 (-0.06)
ResMed: Positive CAT-HF Study Results to Drive ASV Sales
Zacks Equity Research - Zacks Investment Research - Wed May 25, 7:51AM CDT
The positive CAT-HF study results encourage us to expect a rise in demand for the wide range of products offered by ResMed (RMD) in the respiratory care market.
BSX: 24.26 (-0.07), SRDX: 29.48 (+1.24), BAX: 46.28 (+0.10), RMD: 67.06 (-0.06)
Edwards Lifesciences: Q1 Strong, TAVR Prospects Bright
Zacks Equity Research - Zacks Investment Research - Wed May 25, 7:50AM CDT
Edwards Lifesciences (EW) made a strong start to 2016, with its first-quarter results beating estimates on both the fronts.
BSX: 24.26 (-0.07), SRDX: 29.48 (+1.24), BAX: 46.28 (+0.10), EW: 115.85 (-0.02)
Baxter Unveils THERANOVA Dialyser at ERA-EDTA Congress
Zacks Equity Research - Zacks Investment Research - Wed May 25, 7:42AM CDT
Baxter International Inc. (BAX) recently showcased THERANOVA, a new class of medium cut-off (MCO) dialysers.
SRDX: 29.48 (+1.24), IRMD: 17.31 (-0.30), MASI: 59.90 (+0.47), BAX: 46.28 (+0.10)
Baxter (BAX) Raised to Strong Buy on Estimate Revisions
Zacks Equity Research - Zacks Investment Research - Fri May 20, 8:22AM CDT
On May 20, Zacks Investment Research raised Baxter International Inc. (BAX) to a Zacks Rank #1 (Strong Buy).
SRDX: 29.48 (+1.24), MASI: 59.90 (+0.47), BAX: 46.28 (+0.10), EW: 115.85 (-0.02)
SurModics Shares Up 40.8% Since SmarTrend's Buy Recommendation (SRDX)
Comtex SmarTrend(R) - Fri Sep 02, 12:49PM CDT
SmarTrend identified an Uptrend for SurModics (NASDAQ:SRDX) on January 28th, 2016 at $20.44. In approximately 7 months, SurModics has returned 40.84% as of today's recent price of $28.78.
SRDX: 29.48 (+1.24)
SurModics Has Returned 41.2% Since SmarTrend Recommendation (SRDX)
Comtex SmarTrend(R) - Fri Aug 26, 12:17AM CDT
SmarTrend identified an Uptrend for SurModics (NASDAQ:SRDX) on January 28th, 2016 at $20.44. In approximately 7 months, SurModics has returned 41.23% as of today's recent price of $28.86.
SRDX: 29.48 (+1.24)
Surmodics to Present at 5th Annual InvestMNt Conference on August 24
BusinessWire - Tue Aug 16, 7:05AM CDT
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that the Company will present at the 2016 InvestMNt conference sponsored by CFA Society Minnesota.
SRDX: 29.48 (+1.24)
39.0% Return Seen to Date on SmarTrend SurModics Call (SRDX)
Comtex SmarTrend(R) - Thu Aug 11, 12:16AM CDT
SmarTrend identified an Uptrend for SurModics (NASDAQ:SRDX) on January 28th, 2016 at $20.44. In approximately 7 months, SurModics has returned 39.03% as of today's recent price of $28.41.
SRDX: 29.48 (+1.24)
Shares of SRDX Up 36.6% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Aug 03, 12:42PM CDT
SmarTrend identified an Uptrend for SurModics (NASDAQ:SRDX) on January 28th, 2016 at $20.44. In approximately 6 months, SurModics has returned 36.63% as of today's recent price of $27.92.
SRDX: 29.48 (+1.24)
Surmodics IVD Launches Breakthrough StabilBlock(R) Immunoassay Stabilizer
BusinessWire - Mon Aug 01, 6:05AM CDT
Surmodics, Inc. (NASDAQ: SRDX), the global leader in chemical components for in vitro diagnostic (IVD) tests and microarrays, has announced the launch and immediate availability of StabilBlock(R), its most advanced Immunoassay Stabilizer. StabilBlock Immunoassay Stabilizer is the best available reagent for reducing non-specific binding to boost immunoassay signal-to-noise ratios.
SRDX: 29.48 (+1.24)
Surmodics Reports Third Quarter Fiscal 2016 Results
BusinessWire - Thu Jul 28, 6:30AM CDT
--GAAP EPS of $0.30, Non-GAAP EPS of $0.37
SRDX: 29.48 (+1.24)
Myriad Genetics Buys Sividon Diagnostics, Gains EndoPredict
Zacks Equity Research - Zacks Investment Research - Fri Jun 03, 7:59AM CDT
With the global cancer diagnostic market currently expected to grow at a CAGR of 7.6% to $168.6 billion by 2020; we expect the Sividon acquisition to open up more opportunities for Myriad (MYGN) in this market.
BSX: 24.26 (-0.07), SRDX: 29.48 (+1.24), MYGN: 20.65 (+0.21), BAX: 46.28 (+0.10)
SurModics to Present at Jefferies Healthcare Conference
BusinessWire - Wed Jun 01, 7:05AM CDT
SurModics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies, today announced that Gary Maharaj, president and chief executive officer, and Andy LaFrence, vice president of finance and chief financial officer, will make a presentation to the investment community at the Jefferies Healthcare Conference in New York City on Tuesday, June 7, 2016, at 4 p.m. ET (3 p.m. CT).
SRDX: 29.48 (+1.24)
GNC Holdings Q1 Results Weak, Overseas Prospects Bright
Zacks Equity Research - Zacks Investment Research - Wed Jun 01, 7:01AM CDT
GNC Holdings (GNC) made a disappointing start to its first quarter of 2016 with the results squarely missing the Zacks Consensus Estimate.
BSX: 24.26 (-0.07), SRDX: 29.48 (+1.24), BAX: 46.28 (+0.10), GNC: 20.74 (-0.07)
Thermo Fisher to Buy FEI, Boost Electron Microscopy Platform
Zacks Equity Research - Zacks Investment Research - Tue May 31, 7:58AM CDT
The FEI deal is expected to be accretive to Thermo Fisher's (TMO) adjusted EPS by 30 cents in the first full year after close.
BSX: 24.26 (-0.07), SRDX: 29.48 (+1.24), TMO: 151.18 (+0.23), BAX: 46.28 (+0.10), FEIC: 106.61 (+0.05)
IDEXX Laboratories: Strong Instrument Placement Drives Q1
Zacks Equity Research - Zacks Investment Research - Mon May 30, 7:12AM CDT
IDEXX (IDXX) started off 2016 on a strong note, with its first-quarter results squarely beating the Zacks Consensus Estimate.
BSX: 24.26 (-0.07), SRDX: 29.48 (+1.24), BAX: 46.28 (+0.10), IDXX: 114.09 (+0.93)
Cepheid: GeneXpert Placements High, Currency Woes Stay
Zacks Equity Research - Zacks Investment Research - Fri May 27, 6:51AM CDT
Cepheid (CPHD) started 2016 on a promising note with its first-quarter results squarely beating the Zacks Consensus Estimate.
BSX: 24.26 (-0.07), SRDX: 29.48 (+1.24), BAX: 46.28 (+0.10), CPHD: 34.42 (+0.16)
Qiagen, Therawis Diagnostics to Develop Breast Cancer Test
Zacks Equity Research - Zacks Investment Research - Fri May 27, 6:47AM CDT
With the global cancer diagnostic market expected to grow at a CAGR of 7.6% to $168.6 billion by 2020, we expect Qiagen (QGEN) to garner higher profits on account of this collaboration.
BSX: 24.26 (-0.07), SRDX: 29.48 (+1.24), BAX: 46.28 (+0.10), QGEN: 26.63 (+0.17)
ResMed Posts Mixed Q3 Results, Brightree Buyout on Track
Zacks Equity Research - Zacks Investment Research - Thu May 26, 7:35AM CDT
ResMed (RMD) posted a lackluster third-quarter fiscal 2016. Nevertheless, ResMed's segmental as well as geographical performance was strong.
BSX: 24.26 (-0.07), SRDX: 29.48 (+1.24), BAX: 46.28 (+0.10), RMD: 67.06 (-0.06)
ResMed: Positive CAT-HF Study Results to Drive ASV Sales
Zacks Equity Research - Zacks Investment Research - Wed May 25, 7:51AM CDT
The positive CAT-HF study results encourage us to expect a rise in demand for the wide range of products offered by ResMed (RMD) in the respiratory care market.
BSX: 24.26 (-0.07), SRDX: 29.48 (+1.24), BAX: 46.28 (+0.10), RMD: 67.06 (-0.06)
Edwards Lifesciences: Q1 Strong, TAVR Prospects Bright
Zacks Equity Research - Zacks Investment Research - Wed May 25, 7:50AM CDT
Edwards Lifesciences (EW) made a strong start to 2016, with its first-quarter results beating estimates on both the fronts.
BSX: 24.26 (-0.07), SRDX: 29.48 (+1.24), BAX: 46.28 (+0.10), EW: 115.85 (-0.02)
Baxter Unveils THERANOVA Dialyser at ERA-EDTA Congress
Zacks Equity Research - Zacks Investment Research - Wed May 25, 7:42AM CDT
Baxter International Inc. (BAX) recently showcased THERANOVA, a new class of medium cut-off (MCO) dialysers.
SRDX: 29.48 (+1.24), IRMD: 17.31 (-0.30), MASI: 59.90 (+0.47), BAX: 46.28 (+0.10)
Baxter (BAX) Raised to Strong Buy on Estimate Revisions
Zacks Equity Research - Zacks Investment Research - Fri May 20, 8:22AM CDT
On May 20, Zacks Investment Research raised Baxter International Inc. (BAX) to a Zacks Rank #1 (Strong Buy).
SRDX: 29.48 (+1.24), MASI: 59.90 (+0.47), BAX: 46.28 (+0.10), EW: 115.85 (-0.02)
(0)
(0)Scroll down for more posts ▼